Compare Expedia Group Inc (EXPE) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Smith & Nephew plc — how do they compare? Expedia Group Inc trades at $270.26 (market cap $32.42B), while Smith & Nephew plc trades at $27.08 (market cap $11.10B). The key difference: Expedia Group Inc is far larger — about 2.9× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 48 Days and Smith & Nephew plc for 120 Days on average.
| EXPE | SNN | |
|---|---|---|
Market Cap | $32.42B | $11.10B |
Volume | 1,940,671 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $37.17 |
52-Week Low | $188.51 | $26.42 |
Typical Hold Time | 48 Days | 120 Days |
Enterprise Value | $30.98B | $14.13B |
Dividend Yield | 0.71% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $258.86, down 0.38% on the day, amid a bearish technical signal and recent news-driven volatility. The stock shows strong fundamentals with consistent earnings beats, revenue growth to $14.73B in 2025, and robust profitability margins. Recent layoffs and competitive threats from AI travel agents have pressured sentiment, but analyst consensus remains largely positive with a $335.06 price target.
The outlook balances solid financial health and attractive valuation against near-term competitive and execution risks. Upside potential exists if Expedia navigates AI disruption and sustains booking growth, but investor caution is warranted given technical weakness and industry headwinds.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
